Syndax presents updated positive data from beat aml and augment-102 phase 1/2 combination trials of revumenib in patients with acute leukemias at eha 2024 congress

- data continue to support revumenib's potential to enhance current standard of care agents - - 96% crc (23 of 24 pts) observed in beat aml trial exploring revumenib in combination with venetoclax/azacitidine in newly diagnosed mnpm1 or kmt2ar aml - - 52% crc (14 of 27 pts) observed in augment-102 trial of revumenib in combination with fludarabine-cytarabine in acute leukemia patients with r/r mnpm1, nup98r or kmt2ar - waltham, mass. , june 14, 2024 /prnewswire/ -- syndax pharmaceuticals (nasdaq: sndx), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated data from multiple combination trials of revumenib, the company's potent, selective, small molecule menin inhibitor, in patients with acute leukemias.
BEAT Ratings Summary
BEAT Quant Ranking